ReviewDiabetologia2021
Realising the long-term promise of insulin therapy: the DCCT/EDIC study.
Review in Diabetologia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 69 citations in OpenAlex.
- Article
- Metabolic Reprogramming-Driven Cardiovascular Immune Damage: From Glyco-Lipotoxicity and Epigenetic Memory to Multidimensional Cross-Organ Communication Networks.International journal of molecular sciences · 2026Review
- Article
- Decursin ameliorates diabetic kidney disease by attenuating renal epithelial-mesenchymal transition via inhibition of the PI3K/Akt pathway.American journal of translational research · 2026Article
- From population science to the clinic? Limits of epigenetic clocks as personal biomarkers.Epigenomics · 2025Article
- Diabetes and its Silent Partner: A Critical Review of Hyperinsulinemia and its Complications.Current diabetes reviews · 2025Review
- Sex-Based Differences in BMI and LDL-C Trajectories Following Type 1 Diabetes Diagnosis in Youth.Pediatric diabetes · 2025Article
- Impact of a food supplement containingFrontiers in nutrition · 2025Article
- Dose-response relationship between the triglyceride-glucose index and metabolic syndrome risk in patients with type 2 diabetes: a cross-sectional analysis of 1,560 cases.Frontiers in endocrinology · 2025Article
- Cost-effective analysis focused on hypoglycemia of intermittent-scanning continuous glucose monitoring in type 1 diabetes adults: a ISCHIA randomized clinical trial.Diabetology international · 2025Article
- Allogeneic Islet Transplantation: Chronicle of a Death Foretold?Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Concurrent Validity Between EQ-5D and HRQ-6D Measures in Patients with Different Primary Diagnoses.Journal of clinical medicine · 2024Article
- Plasma proteomics in children with new-onset type 1 diabetes identifies new potential biomarkers of partial remission.Scientific reports · 2024Article
- Update: the role of epigenetics in the metabolic memory of diabetic complications.American journal of physiology. Renal physiology · 2024Review
- Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study: Continuing to Build on 40 Years of Diabetes Research.Diabetes care · 2024Article
- Should children with type 1 diabetes really receive statin treatment using the same criteria as for children with familial hypercholesterolaemia?Diabetologia · 2024Article
- Dyslipidaemia as a target for atherosclerotic cardiovascular disease prevention in children with type 1 diabetes: lessons learned from familial hypercholesterolaemia.Diabetologia · 2024Review
- Technology usage and glycaemic outcomes in a single tertiary centre with an ethnically diverse and socioeconomically deprived cohort of children with type 1 diabetes mellitus.Frontiers in clinical diabetes and healthcare · 2024Article
- Transglutaminase 2 in diabetes mellitus: Unraveling its multifaceted role and therapeutic implications for vascular complications.Theranostics · 2024Review
- Simultaneous attenuation of hyperglycemic memory-induced retinal, pulmonary, and glomerular dysfunctions by proinsulin C-peptide in diabetes.BMC medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The introduction of insulin in the treatment of juvenile-onset, now type 1, diabetes mellitus transformed a rapidly fatal disease into a chronic degenerative one. During the insulin-treatment era, long-term microvascular and cardiovascular complications proved to be the bane of existence for people with type 1 diabetes, leading to blindness, kidney failure, amputations, cardiovascular disease (CVD) and premature mortality. The nascent understanding of the link between non-physiologically regulated glucose levels and these complications led to the development of new treatment tools in the 1970s and 1980s that facilitated the delivery of insulin to achieve glucose levels closer to non-diabetic levels. These therapeutic advances set the stage for definitive testing of the glucose hypothesis. The Diabetes Control and Complications Trial (DCCT), supported by the National Institute of Diabetes Digestive and Kidney Diseases, National Institutes of Health (NIH), definitively established the benefits and risks of intensive therapy that substantially lowered mean blood glucose levels, measured by HbA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.